Dataset Information

A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.

ABSTRACT:

Objective

To explore whether red yeast rice is a safe and effective alternative approach for dyslipidemia.

Methods

Pubmed, the Cochrane Library, EBSCO host, Chinese VIP Information (VIP), China National Knowledge Infrastructure (CNKI), Wanfang Databases were searched for appropriate articles. Randomized trials of RYR (not including Xuezhikang and Zhibituo) and placebo as control in patients with dyslipidemia were considered. Two authors read all papers and independently extracted all relevant information. The primary outcomes were serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C). The secondary outcomes were increased levels of alanine transaminase, aspartate aminotransferase, creatine kinase, creatinine and fasting blood glucose.

Results

A total of 13 randomized, placebo-controlled trials containing 804 participants were analyzed. Red yeast rice exhibited significant lowering effects on serum TC [WMD?=?-0.97 (95% CI: -1.13, -0.80) mmol/L, P<0.001], TG [WMD?=?-0.23 (95% CI: -0.31, -0.14) mmol/L, P<0.001], and LDL-C [WMD?=?-0.87 (95% CI: -1.03, -0.71) mmol/L, P<0.001] but no significant increasing effect on HDL-C [WMD = 0.08 (95% CI: -0.02, 0.19) mmol/L, P = 0.11] compared with placebo. No serious side effects were reported in all trials.

Conclusions

The meta-analysis suggests that red yeast rice is an effective and relatively safe approach for dyslipidemia. However, further long-term, rigorously designed randomized controlled trials are still warranted before red yeast rice could be recommended to patients with dyslipidemia, especially as an alternative to statins.

SUBMITTER: Li Y

PROVIDER: S-EPMC4045580 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.

Li Yinhua Y Jiang Long L Jia Zhangrong Z Xin Wei W Yang Shiwei S Yang Qiu Q Wang Luya L

PloS one 20140604 6

<h4>Objective</h4>To explore whether red yeast rice is a safe and effective alternative approach for dyslipidemia.<h4>Methods</h4>Pubmed, the Cochrane Library, EBSCO host, Chinese VIP Information (VIP), China National Knowledge Infrastructure (CNKI), Wanfang Databases were searched for appropriate articles. Randomized trials of RYR (not including Xuezhikang and Zhibituo) and placebo as control in patients with dyslipidemia were considered. Two authors read all papers and independently extracted ...[more]

PMID: 24897342

Similar Datasets

Project description:While several studies have demonstrated the preventive and therapeutic effects of red yeast rice (RYR), a traditional Chinese medicine, on carotid atherosclerosis through the reduction of low-density lipoprotein cholesterol (LDL-C) level and other risk factors, the evidence remains inconsistent. This study aimed to further evaluate the effects of RYR in carotid atherosclerosis. Several databases were searched for original trials of RYR for the treatment of carotid atherosclerosis that reported plaque indicators. Carotid plaque area (AREA), carotid plaque score (SCORE), and intima-media thickness (IMT) were set as the primary outcomes, while lipid profile and safety indicators were set as the secondary outcomes. Meta-analyses were performed on the randomized controlled trials (RCTs) using Comprehensive Meta-analysis software. Heterogeneity was evaluated using the I 2 index and Q statistic. Subgroup, sensitivity, and dose-effect analyses were conducted. Twenty RCTs with 2217 patients were included. Compared to the control group, AREA (SMD = -0.855, 95%CI: -1.259 to -0.451, p < 0.001), IMT (SMD = -0.588, 95%CI: -0.792 to -0.384, p < 0.001), SCORE (SMD = -0.708, 95%CI: -1.135 to -0.282, p = 0.001), LDL-C (SMD = -0.938, 95%CI: -1.375 to -0.502, p < 0.001), triglyceride (SMD = -0.766, 95%CI: -0.980 to -0.551, p < 0.001), and total cholesterol (SMD = -0.858, 95%CI: -1.254 to -0.462, p < 0.001) were significantly decreased and HDL-C (SMD = 0.389, 95%CI: 0.044-0.733, p = 0.027) was significantly increased following RYR therapy. The indicators for safety were not significant and did not differ between the two groups (p > 0.050). Heterogeneities mainly existed for the treatment time or control group setting. Most results showed no changes in the sensitivity analysis. Dose-effect relationships were observed for all indicators except for TC and HDL-C. We concluded that RYR therapy showed considerable efficacy and an acceptable safety profile for the treatment of carotid atherosclerosis in the Chinese population.

Project description:Background: RYR is a commonly used lipid-lowering dietary supplements in Asian and European countries, showing considerable benefits and low toxicity. This quantitative study aims to present high-quality evidence regarding the efficacy and safety of RYR in treating hyperlipidemia, in order to promote its clinical application. Methods: PubMed, embase, and Cochrane Central Register of Controlled Trials databases were systematically searched, and high-quality randomized controlled trials comparing RYR with non-RYR interventions were included. RevMan5.3 software was used to conduct the meta-analysis. Results: A total of 1,012 individuals participated in this study (481 in the experimental and 531 in the control group). In comparison to statins, RYR was more effective in lowering TG (MD, -19.90; 95% CI, -32.22 to -7.58; p = 0.002), comparable in lowering LDL-C and elevating HDL-C, and less effective in lowering TC (MD, 12.24; 95% CI, 2.19 to 22.29; p = 0.02). Compared with nutraceutical, RYR significantly reduced TC (MD, -17.80; 95% CI, -27.12 to -8.48; p = 0.0002) and LDL-C (MD, -14.40; 95% CI, -22.71 to -6.09; p = 0.0007), and elevated HDL-C (MD, 7.60; 95% CI, 4.33 to 10.87; p < 0.00001). Moreover, RYR effectively synergized nutraceutical to further reduce TC (MD, -31.10; 95% CI, -38.83 to -23.36; p < 0.00001), LDL-C (MD, -27.91; 95% CI, -36.58 to -19.24; p < 0.00001), and TG (MD, -26.32; 95% CI, -34.05 to -18.59; p < 0.00001). Additionally, RYR significantly reduced apoB (MD, -27.98; 95% CI, -35.51 to -20.45; p < 0.00001) and, whether alone or in combination, did not increase the risk of adverse events in patients with hyperlipidemia. Conclusion: RYR at 200-4800 mg daily appears to be a safe and effective treatment for hyperlipidemia, effectively regulating blood lipid levels with an exceptional impact on TG. Looking forward, high-quality clinical trials with longer observation periods are required to evaluate the efficacy and safety of RYR as a long-term medication. Systematic Review Registration: (https://www.crd.york.ac.uk/PROSPERO/), identifier (CRD4202128450).

Project description:Phosphogypsum (PG) and titanium gypsum (TG), as a by-product (solid waste) in phosphate fertilizer and titanium dioxide industry, are causing serious environmental hazards. The resource/harmless application of PG and TG is the development trend in the future. The biological function of red yeast (Rho: Rhodotorula mucilaginosa) can effectively reduce the concentration of pollutants in the environment and has the potential of biological flotation/purification of mineral solid waste. In this study, the bioremediation mechanism and safe utilization efficiency of Rho for different contents of PG and TG were explored by using its biological flotation function. The X-ray fluorescence spectrometry (XRF) results showed that F was the main toxic element in PG and TG, and Pb and Cd did not reach the detection limit. The processing capacity of Rho for PG (>10 g/ml) is higher than that of TG (<5 g/ml). After bioleaching by Rho, the proportion of F in PG and TG solid decreased by 61.45-63.79% and 49.45-59.19%, respectively. The results of three-dimensional fluorescence, extracellular polymeric substance (EPS) extraction, X-ray diffraction (XRD), and scanning electron microscopy (SEM) confirmed that Rho could accelerate the release of harmful elements (F) in PG and TG. SEM showed that Rho cells and secretions adhered and wrapped on PG/TG, causing PG/TG decomposition and fragmentation. In addition, the adsorption of EPS and the formation of Ca5(PO4)3F are two main ways for Rho to remove F. Furthermore, under the condition of high concentration bioleaching, Rho can accelerate the release and utilization of P in PG, which is not only for the re-precipitation of Ca5(PO4)3F but also conducive to the reproduction and utilization of microorganisms. Meanwhile, the purification/safe reuse of PG by Rho is easier than that of TG. Therefore, the toxicity of PG and TG bioleaching by Rho can be greatly reduced, suggesting the huge potential of Rho in soil improvement and remediation.

Project description:Red rice bran extract (RRBE) is rich in phytonutrients and has been shown to have anti-diabetic, anti-inflammatory, and antioxidant properties. However, its anti-hepatic steatosis and anti-dyslipidemic properties have not been thoroughly investigated. This study examined the aforementioned properties of RRBE, the underlying mechanism by which it alleviated non-alcoholic fatty liver disease in high-fat diet (HFD)-fed mice, and its major bioactive constituents. The mice were divided into four groups based on their diet: (1) low-fat diet (LFD), (2) LFD with high-dose RRBE (1 g/kg/day), (3) HFD, and (4) HFD with three different doses of RRBE (0.25, 0.5, and 1 g/kg/day). The administration of RRBE, especially at medium and high doses, significantly mitigated HFD-induced hepatosteatosis and concomitantly improved the serum lipid profile. Further, RRBE modified the level of expression of lipid metabolism-related genes (adipose triglyceride lipase (ATGL), cluster of differentiation 36 (CD36), lipoprotein lipase (LPL), liver X receptor alpha (LXRα), sterol regulatory element-binding protein-1c (SREBP-1c), SREBP-2, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and carnitine palmitoyltransferase 1A (CPT1A)) in hepatic or adipose tissues and improved the expression of hepatic high-density lipoprotein cholesterol (HDL-C) cmetabolism-related genes (hepatic lipase (HL) and apolipoprotein A-ǀ (ApoA-ǀ)). RRBE also attenuated markers of liver injury, inflammation, and oxidative stress, accompanied by a modulated expression of inflammatory (nuclear factor-kappa B (NF-κB) and inducible nitric oxide synthase (iNOS)), pro-oxidant (p47phox), and apoptotic (B-cell lymphoma protein 2 (Bcl-2)-associated X and Bcl-2) genes in the liver. High-performance liquid chromatography analyses indicated the presence of protocatechuic acid, γ-oryzanol, vitamin E, and coenzyme Q10 in RRBE. Our data indicate that RRBE alleviates HFD-induced hepatosteatosis, dyslipidemia, and their pathologic complications in part by regulating the expression of key genes involved in lipid metabolism, inflammation, oxidative stress, and apoptosis.

Dataset Information

A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.

Objective

Methods

Results

Conclusions

Publications

A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets